Identification of covariates influencing therapy response in primary membranous glomerulonephritis

Identification of covariates influencing therapy response in primary membranous glomerulonephritis - PrimGn

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00031479

Enrollment

150

Registered

2023-03-16

Start date

2022-12-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary membranous glomerulonephritis

Interventions

Group 1: Retrospective analysis of patients diagnosed with "primary membranous glomerulonephritis". Patients are analysed meeting the following inclusion criteria: age = 18 years, treatment within the

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: biopsy-proven primary membranous glomerulopathy (MGN), detection of antoantibodies (phospholipase-A2-receptor [PLA2R], or thrombospondin type1 domain-containing 7 A [THSD7A]), nephrotic-range proteinuria (urine protein to creatinine ratio [UPCR] = 3.5 g/g or Serum Albumin = 3.5 g/dl).

Exclusion criteria

Exclusion criteria: Inclusion criteria are not met

Design outcomes

Primary

Measure	Time frame
Time until endpoint is reached: proteinuria < 0,5 g/g or serum albumin = 4 g/dl (in dependance of age, sex, BMI, renal fuction, PLAR2-antibody status, immunsuppressive or non-immunsuppressive therapy)	—

Secondary

Measure	Time frame
eGFR improvement (+ 20% in reference to baseline)	—

Countries

Germany

Contacts

Public ContactThomas Welte

Universitätsklinikum Freiburg

thomas.welte@uniklinik-freiburg.de004976127034010

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026